HORSHAM, PennsylvaniaCell Pathways, Inc. has announced that the
National Cancer Institute is sponsoring two phase II studies of the company’s
investigational drug Aptosyn (exisulind) in combination therapies for lung
cancer. The Cancer and Leukemia Group B (CALGB) is studying Aptosyn in
combination with eto-poside (VePesid) and carboplatin (Paraplatin) in
patients with extensive-stage small-cell lung cancer. The Eastern Cooperative
Oncology Group (ECOG) is investigating Aptosyn in combination with
gemcitabine (Gem-zar) and carboplatin in patients with advanced
non-small-cell lung cancer.
Aptosyn selectively triggers apopto-sis in cancerous and precancerous
cells but not in normal cells by inhibiting certain cyclic GMP
phosphodiesterases that are expressed at high levels in the abnormal cells.